Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the develo
NanoViricides inks regulatory services deal to advance orphan drug strategy for antiviral NV-387
04:18am, Monday, 01'st Dec 2025
NanoViricides (NYSE-A:NNVC) said on Monday it signed a master services agreement with regulatory consulting firm Only Orphans Cote LLC to support the...
NanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trials
10:15am, Monday, 17'th Nov 2025
NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for mon
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
08:30am, Monday, 17'th Nov 2025
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter e
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
08:30am, Friday, 14'th Nov 2025
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs t
NanoViricides closes $6M offering to fund operations
08:43am, Thursday, 13'th Nov 2025
NanoViricides (NYSE-A:NNVC) said on Thursday it had closed a $6 million registered direct offering with a single healthcare institutional investor to support working capital and general corporate purp
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
05:01pm, Wednesday, 12'th Nov 2025
SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agree
MinRes strikes lithium JV with POSCO Holdings, banking US$765M to cut debt and fund growth
06:51am, Wednesday, 12'th Nov 2025
Mineral Resources Ltd (ASX:MIN) has agreed key terms with South Korea’s POSCO Holdings to sell a 30% stake in a new incorporated joint venture that will own...
Visa and Mastercard reach proposed settlement with US merchants, ending decades-long fee dispute
10:21am, Tuesday, 11'th Nov 2025
Visa Inc (NYSE:V, ETR:3V64) and Mastercard Inc (NYSE:MA) have reached a proposed settlement with US merchants aimed at resolving more than two decades of...
NanoViricides raises $6M in direct offering with institutional investor
08:51am, Tuesday, 11'th Nov 2025
NanoViricides (NYSE-A:NNVC) said on Tuesday it has entered into a securities purchase agreement with a single healthcare institutional investor to raise about $6 million through a registered direct o
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
08:30am, Tuesday, 11'th Nov 2025
SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a s
NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC
09:51am, Monday, 10'th Nov 2025
NanoViricides (NYSE-A:NNVC) announced that it has received approval to begin its Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Repub
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of N
NanoViricides' NV-387 shows broad antiviral potential, says Zacks
08:33am, Friday, 07'th Nov 2025
Analysts at Zacks have issued a new report on clinical stage biotech NanoViricides (NYSE-A:NNVC), saying that its lead drug candiate NV-387 shows broad-spectrum antiviral potential ahead of a Phase 2
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"),
